SRC family kinase (SFK) inhibitor dasatinib improves the antitumor activity of anti-PD-1 in NSCLC models by inhibiting Treg cell conversion and proliferation
Palabras clave :
Lung neoplasms
Tumor microenvironment
Lymphocytes
Tumor-infiltrating
Drug evaluation
Preclinical
Fecha de publicación :
2021
Nota:
This is an open access article distributed in accordance with the
Creative Commons Attribution Non Commercial (CC BY- NC 4.0) license
Cita:
Redín-Cabodevilla, M. (María Esther); Garmendia-Iturbe, I. (Irati); Lozano-Moreda, T. (Teresa); et al. "SRC family kinase (SFK) inhibitor dasatinib improves the antitumor activity of anti-PD-1 in NSCLC models by inhibiting Treg cell conversion and proliferation". Journal for Immunotherapy of Cancer. 9 (3), 2021, e001496
Aparece en las colecciones:
Estadísticas e impacto
0 citas en
0 citas en
Los ítems de Dadun están protegidos por copyright, con todos los derechos reservados, a menos que se indique lo contrario.